Rewatched the clip - summary- I just rewatched

Rewatched the clip - summary-

I just rewatched the clip on DVR as I missed it initially (thanks thriftycents for the quick trigger finger there!). The quick one-liner is that he said nothing new that anyone on THIS board doesn't already know, we are all WELL aware of everything going on in the company. The stock is up because no one else knows about our small co and this goes to show you how quickly the potential energy stored in this stock on any sort of approval or wider positive media coverage can turn into kinetic energy in the stock price.

Who blinked and missed it?

-Nader actually did a very nice job presenting a quick pitch of LL in both the Covid & HIV indications with a brief mention of cancer as well. He came across enthusiastic but professional - nice to see him not lose his temper w/ Cavuto (not that he was given a reason to, but still )

-Spoke briefly about the strong results in M/M
-Mentioned something regarding how they did such & such, like Regeneron, i.e. CYDY is in same ballpark as these other companies (I liked that he said REGN in the same breath, gives us legitimacy in the avg. layman's mind)
-Mentioned Phase 3 S/C results expected at end of next week and played it up a bit (let's hope it works out as he pitched it may) saying potential approval if results are what they expect
-Mentioned the stellar results with the 70 EIND's, said more than any other drug
-Mentioned the safety with 1000 patients
-Mentioned how it's been under development for 6 years, and also 10 years before that by Progenics (I think that's the name) - aka it's not a fly-by-night operation like some of these others
-Mentioned that HIV should be approved as well and how LL is effective as a monotherapy w/ no other drugs needed
-Mentioned how LL is a self-injectable shot

So, basically, crushed it in a 2-3 minute time slot, got our name out there in a real way (not Proactiv), said all the right things, was promotional but obviously for good reason and as a CEO should be imo. A solid win for a change and lights the fire.

The benefit also is the more eyes that are on the interim, the more likely the FDA may not be able to play games (assuming they do) with any sort of solid p-value as folks on this board have laid out...

I caveat the above with the fact that they can't release interim data at the end of next week unless the trial is stopped for efficacy (I think), if the FDA says continue to the end of the trial, I don't think anyone will be told anything other than that...correct me if I'm wrong. But again, I'm all for more eyes on our co, whether we are approved in a week or in 1-2 months. Helps w/ uplist chances as well imo.

Here here for Lord Nader!